England to Review Rejection of Lilly Alzheimer’s Drug for NHS

NICE will reconsider its rejection of Eli Lilly’s Alzheimer’s drug donanemab (marketed as Kisunla) for NHS use after Lilly won an appeal; the drug is authorized in the UK but currently only available privately. The re-review could reopen public reimbursement in the UK and modestly affect Eli Lilly’s potential UK revenues and NHS spending, but outcome will hinge on price versus demonstrated clinical benefit.

Analysis

The successful appeal forces NICE back to the negotiating table, turning a binary rejection into a multi-month value-capture process. The key leverage will be how much list price concession Lilly is willing to make versus an outcomes- or indication-limited NHS rollout (e.g., restricted to early MCI/amyloid-positive cohorts); each incremental percentage point in negotiated net price translates to material changes in peak UK revenue but also sets a precedent for EU payors within 6–18 months.

Second-order winners include diagnostics (amyloid PET, plasma biomarkers) and infusion/administration services that enable targeted prescribing; suppliers with flexible capacity can win if uptake is limited but concentrated. Conversely, competitors with marginally better trial metrics could see shorter-term investor outperformance if NICE pivots to subgroup evidence, which would advantage drugs with cleaner efficacy-to-price ratios.

Tail risks are asymmetric and time-staggered: a favorable decision with a steep discount still meaningfully derisks commercial launch over 12–24 months, while another rejection or demand for outcomes-based contracts could compress realized revenue and delay prescriber uptake for years. Watch two catalysts closely — NICE’s requested evidence set and any novel head‑to‑head or real‑world effectiveness data expected over the next 6–12 months — both can flip valuations materially for incumbents and late movers in the amyloid class.

Key Decisions for Investors

• Long LLY (6–12 months): initiate a directional position via a 9–12 month call spread to cap premium (buy calls / sell higher strike). Rationale: appeal success increases probability of at‑least partial NHS access or meaningful price negotiation that re-rates pipeline optionality. Risk: regulatory/social backlash or required steep discounts; reward: asymmetric if NICE approval triggers precedent across Europe.
• Pair trade — Long LLY / Short BIIB (12–18 months): overweight Lilly versus Biogen to capture idiosyncratic upside from a successful UK negotiation while hedging class-wide outcomes risk. Position size: modest (2–4% net risk) given correlated clinical/regulatory exposures. Risk: class-level approvals boost both names; cap losses with stops or capped call spreads.
• Event hedge: buy protection on synthetic long via OTM puts on LLY or reduce delta with call spreads ahead of NICE’s next procedural milestone (expected within 3–9 months). This monetizes downside from a repeat rejection or onerous contract terms while keeping upside exposure if the re-review is constructive.
• Sector steering: add exposure to diagnostics/biomarker players (e.g., large-cap imaging/diagnostics names) on pullbacks — time horizon 6–24 months — to capture increased testing demand if access expands. Keep allocations small and liquidity high; outcome-based rollouts could concentrate demand and compress time to positive cash flow.